
doi: 10.3205/14gaa19
Background: In Germany newly authorized pharmaceuticals have to undergo the procedure of the early benefit assessment since 2011. The assessment focuses on patient benefits and the findings of the early assessment to form the basis for subsequent price negotiations. The assessment is solely based on[for full text, please go to the a.m. URL]
21. Jahrestagung der Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie, 9. Deutscher Pharmakovigilanztag
ddc: 610, 610 Medical sciences; Medicine
ddc: 610, 610 Medical sciences; Medicine
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
